Home » Stocks » ADC Therapeutics SA

ADC Therapeutics SA (ADCT)

Stock Price: $33.58 USD 0.08 (0.24%)
Updated Sep 25, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 2.37B
Revenue (ttm) 2.34M
Net Income (ttm) -116.48M
Shares Out 70.72M
EPS (ttm) n/a
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Sep 25, 2020
Last Price $33.58
Previous Close $33.50
Change ($) 0.08
Change (%) 0.24%
Day's Open 34.00
Day's Range 33.16 - 34.57
Day's Volume 225,558
52-Week Range 28.50 - 56.59

More Stats

Market Cap 2.37B
Enterprise Value 2.26B
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 70.72M
Float 31.58M
EPS (basic) n/a
EPS (diluted) n/a
FCF / Share -1.83
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 1.17M
Short Ratio 11.31
Short % of Float 5.59%
Beta n/a
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 1,014.80
PB Ratio 12.07
Revenue 2.34M
Operating Income -119.40M
Net Income -116.48M
Free Cash Flow -122.66M
Net Cash 110.52M
Net Cash / Share 1.56
Gross Margin n/a
Operating Margin -5,102.52%
Profit Margin -4,977.90%
FCF Margin -5,241.71%
ROA -34.24%
ROE -126.46%
ROIC 1,251.80%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (3)

Buy 3
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

Current: $33.58
Target: 53.00
*Average 12-month price target from 1 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Revenue Growth105.26%-
Gross Profit2.341.14
Operating Income-119-126
Net Income-116-123
Shares Outstanding66.87-
Earnings Per Share-2.36-2.64
Operating Cash Flow-122-122
Capital Expenditures-0.36-0.94
Free Cash Flow-123-123
Cash & Equivalents116139
Total Debt5.03-
Net Cash / Debt111139
Book Value111126
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name ADC Therapeutics SA
Country Switzerland
CEO Christopher John Martin

Stock Information

Ticker Symbol ADCT
Stock Exchange New York Stock Exchange
Sector Healthcare
Industry Biotechnology
Unique Identifier NYSE: ADCT
IPO Date May 15, 2020


ADC Therapeutics SA, a clinical-stage oncology-focused biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its lead product candidates are ADCT-402, an ADC that is in a Phase II clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma; and ADCT-301, an ADC that is in a pivotal Phase II clinical trial for the treatment of relapsed or refractory Hodgkin lymphoma, non-Hodgkin lymphoma, and solid tumors. The company also develops clinical-stage product candidates, such as ADCT-601 and ADCT-602, as well as preclinical product candidates, including ADCT-701 and ADCT-901. ADC Therapeutics SA has a collaboration and license agreement with Genmab A/S. The company was incorporated in 2011 and is headquartered in Epalinges, Switzerland.